checkAd
    Startseite > Aktien > Kezar Life Sciences > Nachrichten
    Kezar Life Sciences Aktie
    0,8049
     
    USD
    +1,89 %
    +0,0149 USD
    Letzter Kurs 27.04.24 Nasdaq
    0,8023
     
    USD
    200 STK
    Geldkurs 26.04.24
    0,8049
     
    USD
    1.400 STK
    Briefkurs 26.04.24
    ISIN: US49372L1008 · WKN: A2JPE7 · SYM: KZR · USA

    Neueste Nachrichten

    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    08.04.24 · Business Wire (engl.) · Kezar Life Sciences
    Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
    14.03.24 · Business Wire (engl.) · Kezar Life Sciences
    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    08.03.24 · Business Wire (engl.) · Kezar Life Sciences
    Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
    28.02.24 · Business Wire (engl.) · Kezar Life Sciences
    Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
    27.02.24 · Business Wire (engl.) · Kezar Life Sciences
    Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
    21.11.23 · Business Wire (engl.) · Kezar Life Sciences
    Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
    13.11.23 · Business Wire (engl.) · Kezar Life Sciences
    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    03.11.23 · Business Wire (engl.) · Kezar Life Sciences
    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    09.10.23 · Business Wire (engl.) · Kezar Life Sciences
    Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
    03.10.23 · Business Wire (engl.) · Kezar Life Sciences
    Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia
    21.09.23 · Business Wire (engl.) · Kezar Life Sciences
    Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
    31.08.23 · Business Wire (engl.) · Kezar Life Sciences